The rs1403543 Polymorphism of AGTR2, Which Encodes the Type-2 Angiotensin II Receptor, and Left Ventricular Mass in Polish Full-Term Newborns
by
,
Iwona Gorący
1, 
Karol Miler
1,
Klaudyna Lewandowska
1,
Monika Rychel
1,
Beata Łoniewska
2 and
Andrzej Ciechanowicz
1,*
1
Department of Clinical and Molecular Biochemistry, Pomeranian Medical University, 70-111 Szczecin, Poland
2
Department of Neonatal Diseases, Pomeranian Medical University, 70-111 Szczecin, Poland
*
Author to whom correspondence should be addressed.
Genes 2025, 16(5), 518; https://doi.org/10.3390/genes16050518
Submission received: 4 April 2025
/
Revised: 25 April 2025
/
Accepted: 26 April 2025
/
Published: 29 April 2025
(This article belongs to the Special Issue 15th Anniversary of Genes: Feature Papers in the “Molecular Genetics and Genomics” Section)
Abstract
:Background/Objectives: Left ventricular hypertrophy is a significant independent risk factor for increased cardiovascular morbidity and mortality. There are some reports indicating an association of rs1403543 (1675G>A) polymorphism in the AGTR2 gene, which encodes the type-2 angiotensin II receptor, with left ventricular hypertrophy or increased left ventricular mass (LVM) in adults. The aim of this study was to analyze the possible association of the AGTR2:rs1403543 polymorphism with LVM in full-term Polish healthy newborns. Methods: The study group comprised 207 consecutive, full-term, healthy newborns. LVM was assessed, on the 3rd day after birth, from the M-mode echocardiographic measurements of left ventricular dimensions using the Penn convention, with the Huwez et al.-modified equation mode. The AGTR2 polymorphism was identified by PCR-RFLP in genomic DNA extracted from cord blood leukocytes. Results: There were no significant differences in clinical and echocardiographic characteristics of male newborns in regard to the AGTR2:rs1403543 polymorphism. However, the LVM/body mass ratio in female newborns carrying at least one A allele (i.e., with genotype GA or AA) was significantly lower as compared to its value in reference (GG) homozygotes. In addition, in female newborns, the frequency of AGTR2 genotypes with at least one A allele was significantly higher in the lower tertile of LVM/body mass or LVM/body surface area (calculated using the Mosteller formula) ratios as compared with upper tertiles. Conclusions: Our results suggest that the AGTR2:rs1403543 polymorphism may be associated with the physiological variability of cardiac mass in female newborns.
1. Introduction
Left ventricular hypertrophy (LVH) is recognized when the left ventricular mass index (LVMI), calculated as the left ventricular mass (LVM) divided per body surface area (BSA), is >95 g/m2 in women or >115 g/m2 in men [1,2]. A number of studies have demonstrated that LVH is a significant independent risk factor for increased cardiovascular morbidity and mortality and, therefore, a major public health burden, especially in light of an aging population [3]. The results of several studies have suggested that approximately 30% to 70% of cardiac mass variability can be explained by heredity [4,5,6,7,8].
The renin–angiotensin system (RAS) is both a major regulator of maternal–fetal health [9] as well as the crucial endocrine element in the regulation of renal and cardiovascular homeostasis [10]. One crucial element of this homeostasis is the action of angiotensin II (ANGII) as a ligand via two types of receptors. Stimulation of the type-1 angiotensin II receptor (AT1R) results, i.a., in an increase of blood pressure and in induction of cardiac hypertrophy and fibrosis, while activation of the type-2 receptor (AT2R) gives opposing effects [10].
The expression of AT2R is high in the neonatal heart and declines after birth (for review, see [11]). It is worth noting that the heart masses of 7-day-old and 14-day-old AT2R-knockout mice were significantly higher than those of age-matched control mice. However, the heart-to-body-mass ratio in AT2R-deficient mice in this early postnatal period was significantly lower than those of age-matched control mice [12]. In addition, the AT2R deficiency resulted in a stronger increase in blood pressure in response to infusion of angiotensin II [13,14,15]. This suggests that the stimulation of AT2R by angiotensin II affects postnatal cardiac growth, possibly via reducing body mass gain and lowering blood pressure [10,12].
The type-2 angiotensin II receptor in humans is encoded by the AGTR2 gene located at chromosome Xq23. The common AGTR2:rs1403543 polymorphism gives a transition of guanine (G) to adenine (A) 1332 base pairs (bp) upstream of the translation start codon (-1332G>A), also known as 1675G>A (e.g., G-to-A transition located 1675 bp downstream of the transcription start) [16]. The dbSNP variant details give AGTR2:rs1403543 as being located at NC_000023.11:g.116170939G>A according to genome assembly GRCh38.p14 chr X and as having two transcripts with locations NM_000686.5:c.-95-29G>A and NM_001385624.1:c.-36+123G>A. In this article, we will refer to this single nucleotide variant as rs1403543 or 1675G>A. The A allele has a global ALFA allele frequency of 52%, and the reference G allele has 48% (a T allele being extremely rare; dbSNP) [17].
So far, only a few reports have focused on the analysis of the association between AGTR2:rs1403543 polymorphism and LVMI and/or LVH and, in addition, these reports have yielded contradictory results [18,19,20,21,22,23,24,25]. In 2001, Schmieder et al. showed, in a group of 120 young males of European descent, that hypertensive (but not normotensive) subjects hemizygous for the AGTR2:1675A allele had a greater LVMI as compared with hypertensives with the reference AGTR2 variant (with the 1675G allele) [18]. One year later, in the GLAOLD (Glasgow Heart Scan Old) study of subjects aged 55–74 years, Herrmann et al. found that the frequency of AGTR2:1675A allele carriers was significantly higher in males with LVH than in those without left ventricular hypertrophy, and this effect was not observed in females [19]. In contrast, Alfakih et al. reported a significantly higher prevalence of GG homozygous females and G hemizygous males among a group with magnetic resonance imaging (MRI)-assessed LVH as compared to a group without LVH (heterozygous females were excluded from the analysis) [20]. Also, in EPOGH men (but not in women), LVMI increased significantly with higher sodium excretion (4.2 g/m2 per 100 mmol) in carriers of the reference (1675G) allele, with the opposite tendency in males with the AGTR2:1675A allele [21]. In 2007, Ott et al. reported a lower LVM in males with the 1675G variant who were particularly susceptible to LVM modification by increased salt intake [22]. In contrast, Orlowska-Baranowska et al. found no significant association of AGTR2:1675G>A polymorphism with LVH in Polish patients with aortic stenosis [23]. Huber et al. also revealed no significant association of this AGTR2 variant with LVMI in treated patients with arterial hypertension in Germany [24]. However, in patients with hypertrophic cardiomyopathy, Carstens et al. reported an allele-dependent modulating effect of the AGTR2:rs1403543 polymorphism on LVH (with a decrease in wall thickness by ~0.5 mm with each 1675A allele) which was independent of such covariates as causal mutation of hypertrophic cardiomyopathy or blood pressure [25]. It has not escaped our notice that all the above-mentioned studies concerning the association of the AGTR2:rs1403543 polymorphism and LVM have been carried out in adults. However, it is worthy to underline that reliable evidence suggests that cardiovascular disease (CVD) begins early in life [26,27]. There have been reports of association of CVD risk factors in childhood with both increased cardiac growth in children [28,29] and LVH in adults [30,31]. Therefore, the aim of our study was to analyze the possible association of the AGTR2:rs1403543 polymorphism with echocardiographically measured left ventricular mass in full-term Polish healthy newborns.
2. Materials and Methods
2.1. Newborns
The criteria for newborn eligibility in the present study as well as newborn cord blood (500 μL) collection for the isolation of genomic DNA have been described before [32,33]. In brief, the study group comprised 207 healthy Polish newborns (96 females and 111 males), born between 38 and 40 weeks (inclusive) of gestation to healthy women with uncomplicated pregnancies. The sex of the newborn, body mass (BM; kg) and body length (BL; m) were taken from standard hospital records. Body surface area (BSA; m2) was calculated using the Mosteller formula [34]:
BSA = 0.0167 × (100 × BL)0.5 × BM0.5
All the studied newborns, on the third day after delivery, underwent transthoracic echocardiography as described previously [6,35]. Measurement techniques followed American Society of Echocardiography conventions. Left ventricular masses were estimated from echocardiographic left ventricular dimensions using the Penn convention, with the equation modified by Huwez et al. [36]:
where IVST, LVPWT and LVID denote interventricular septal thickness, left ventricular posterior wall thickness and left ventricular internal dimension, respectively. To give standardized parameters, the left ventricular mass was divided by body mass (LVM/BM, g/kg), body length (LVM/BL, g/m) or body surface area (LVM/BSA, g/m2). The study was conducted in accordance with the latest Declaration of Helsinki (2024) and was approved by the bioethics committee at the Pomeranian Medical University in Szczecin, Poland. Parental informed consent for newborn control data was obtained for each newborn.
LVM [g] = 1.04 × [(IVST [mm] + LVPWT [mm] + LVID [mm])3 − LVID [mm]3]
2.2. AGTR2:rs1403543 Genotyping
Genomic DNA was isolated from cord blood as described previously [32,33]. For the genotyping of the AGTR2:rs1403543 polymorphism, a PCR-RFLP (polymerase chain reaction–restriction fragment length polymorphism) method was applied with 5′-GGAAAGTAGAACATACATTAAATG-3′ as the forward primer, and with 5′-CCTGTAAGAGAA ACAGCAGCTAAAGAATT′-3′ as the reverse primer (both primers from TIB MOL BIOL, Poznań, Poland). The AGTR2 amplicons were subsequently digested with the EcoRI restriction enzyme (Thermo Fisher Scientific, Waltham, MA, USA). The PCR product was cut into fragments of 95 base pairs (bp) and 25 bp if the 1675G reference allele was present or remained uncut (with an amplicon of 120 bp in length) with the 1675A allele. Both electrophoretic separation of the restriction products and the verification of PCR-RFLP results were carried out as described before [33].
2.3. Statistical Analyses
Normality of the quantitative data was assessed by Kolmogorov–Smirnov or Lilliefors tests. As most quantitative variables were not normally distributed, all are presented as medians with minimum and maximum values. Quantitative data were compared using Mann–Whitney tests or Kruskal–Wallis tests, if necessary. Categorical data were assessed using chi-squared tests. Statistical significance was defined as p < 0.05. All data were analyzed using a data analysis software system (Statistica, version 13, TIBCO software, Palo Alto, CA, USA).
3. Results
There were 28 (29.2%) GG homozygotes, 45 (46.9%) GA heterozygotes and 23 (23.9%) AA homozygotes among female newborns, and the frequency of the AGTR2:1675A allele in this group was 47.4%. The AGTR2:rs1403543 genotype distribution in female newborns was consistent with the Hardy–Weinberg equilibrium (p = 0.557). There were 58 (52.2%) male newborns hemizygous for the AGTR2:1675G reference allele and 53 (47.8%) male newborns with the 1675A allele.
Clinical and echocardiographic newborn characteristics are shown in Table 1. There were no significant differences between females and males in terms of body length, left ventricular dimensions (IVST, LVPWT and LVID) or LVM and LVM indices (LVM/BM, LVM/BL and LVM/BSA). Only body mass (BM) and body surface area (BSA) in male newborns were significantly higher than in females.
There were no significant differences in the values of clinical and echocardiographic variables in female newborns in regard to AGTR2:rs1403543 genotype except for LVM/BM. The LVM/BM in female newborns carrying at least one 1675A allele (with a GA or AA genotype) was significantly lower as compared to its value in females homozygous for the reference AGTR2 allele (Table 2 and Figure 1).
Other than for BSA, there were no significant differences in clinical and echocardiographic characteristics of male newborns in regard to AGTR2:rs1403543 hemizygosity. The BSA in male newborns hemizygous for the AGTR2:1675A allele was significantly lower as compared to males with the reference variant (with the 1675G allele) (Table 3). Further, separately for females and males, the distributions of AGTR2:rs1403543 polymorphism in tertiles of LVM indices were analyzed. No significant associations were found both in females or males between the distributions of AGTR2:1675G>A variants or tertiles of LVM indices except for LVM/BL and LVM/BSA in female newborns (Table 4 or Table 5, respectively). The frequency of AGTR2 genotypes with at least one AGTR2:1675A allele was significantly higher for both LVM/BM and LVM/BSA in female newborns from the lower tertile as compared with subjects from the upper tertile (Table 4).
Finally, after exclusion of GA heterozygous female newborns (due to the presumed effect of random inactivation of the one of the X chromosomes in females), we assessed the differences between GG/G and AA/A subjects (GG homozygous females + G hemizygous males versus AA homozygous females + A hemizygous males).
After the exclusion of GA heterozygotes, no significant differences between female newborns and male newborns were found in the values of body length, left ventricular dimensions or LVM and LVM indices. Only the body mass (BM) and body surface area (BSA) in male newborns were significantly higher as compared to females (Table 6).
There were no significant differences in the values of clinical and echocardiographic variables between subjects carrying the 1675G allele and carriers of the 1675A variant (Table 7).
No significant differences in the frequency distributions of the AGTR2 polymorphism with regard to the tertiles of LVM indices were found in the comparison of GG/G with AA/A newborns (Table 8).
4. Discussion
This study has focused on the analysis of the association between the AGTR2:rs1403543 polymorphism and left ventricular mass (LVM) in full-term healthy newborns. The results revealed no significant association of AGTR2 variants with LVM indices in male newborns, but they were associated with a lower LVM in female newborns carrying the 1675A allele. Our results with female newborns are consistent with those of a previous study by Alfakih et al. [20], who reported both a lower LVM index in AA/A subjects (i.e., in AA females and A males) than in GG/GA females and an excess of GG/G subjects among a group of patients with MRI-determined left ventricular hypertrophy. In addition, in a family cohort of patients with hypertrophic cardiomyopathy (HCM), Carstens et al. found a decrease in average wall thickness of ~0.5 mm with each AGTR2:1675A allele independent of the effects of the primary HCM causal mutation, blood pressure and other hypertrophy covariates [24]. However, it is also worthy to note that other studies either did not confirm in women an association of the 1675A AGTR2 allele with LVM [21] or LVH [19,23,25] or revealed such association in males only [18,19,22]. In contrast, Kuznetsova et al. found that LVMI increase (related to higher salt intake) was significantly higher in males with the 1675G variant as compared to males with the A allele [21]. Therefore, taking into consideration the above discrepancies, we decided to carry out our study in healthy newborns born at term. The reasons for this are that newborns have a relative lack of exposure (or at least no long-term exposure) to confounding environmental factors, coexisting diseases or medication, and full-term healthy newborns are a more appropriate target group to study the association between genetic polymorphisms and cardiovascular intermediate phenotypes such as cardiac mass [37]. Last, but not least, an argument in favor of performing an association analysis of X-chromosome-located genes (such as AGTR2) in female newborns is the low frequency of nonrandom (skewed) X-chromosome inactivation (XCI) in female newborns [38] (although, even so, in one analysis, heterozygotes were excluded). In addition, for the rs1403543 biallelic polymorphism of the AGTR2 gene located at chromosome X, women have three possible genotypes (GG, GA or AA), while men are hemizygous either for 1675G or the 1675A allele. Therefore, to ensure equal gene dosage, we carried out an association analysis of AGTR2 polymorphism with LVM indices in the combined group (consisting of female and male newborns) after exclusion of heterozygous female newborns as in the study by Alfakih et al. [20].
The AGTR2 gene spans approximately 5 kb and consists of three exons. Only the third exon encompasses the complete protein-coding sequence of 363 amino acids of the G-protein-coupled receptor [39]. The AGTR2 gene 5′-flanking region contains typical eukaryotic promoter sequence motifs but also an Interferon Consensus Sequence Binding Protein (ICSBP) site and a putative Embryonal, Long Terminal Repeat Binding Protein (ELP) site what suggests a possible unusual regulation of AGTR2 expression [39]. In addition, Warnecke et al. have indicated that sequence elements in intron 1 of the AGTR2 gene are necessary for its efficient transcription [40]. Kuznetsova et al. have suggested that the AGTR2:rs1403543 polymorphism located in intron 1 is probably functional [21]. However, the molecular effects of AGTR2:1675G>A transition have been not fully elucidated and remain unclear. In 1999, Nishimura et al. pointed out that the AGTR2:rs1403543 transition is located within the lariat branchpoint motif of intron 1, which disrupts the efficiency of mRNA splicing. The authors also reported that cDNA from code containing the A allele consists of all three exons but cDNA from code with the G allele is 60 nucleotides shorter due to a lack of exon 2. In addition, the amount of mRNA transcribed from the G allele code was significantly lower as compared with mRNA from the A allele code [41]. However, six years later Warnecke et al. indicated that the AGTR2:1675G>A polymorphism modulates receptor protein expression rather than mRNA splicing. Using in vitro transfection assays with a luciferase reporter gene, the authors revealed that subjects carrying the 1675G allele may express higher levels of the type-2 angiotensin II receptor protein than those with the A allele [42]. It is not possible to rule out that the intronic rs1403543 polymorphism affects transcription of this gene per se but, additionally, it is in close linkage disequilibrium with other AGTR2 variants of real functional importance, as discussed below.
Our analyses (using https://www.ensembl.org/Homo_sapiens/Tools/LD, accessed on 3 April 2025) in European-descent populations from the 1000 Genomes (1KG) Project have indicated that rs14003543 is in tight (r2 0.785, D′ 0.957), very tight (r2 0.842, D′ 0.999) or even in complete (r2 1.000, D′ 1.000) linkage disequilibrium (LD) with the AGTR2:rs11091046 polymorphism (GRCh38.p14 chr X:NC_000023.11:g.116173873A>C (dbSNP); also known as 3123C>A or 4599C>A [37] for TSI (Toscani in Italy), CEU (Utah Residents with Northern and Western European ancestry) or GBR (British in England and Scotland), respectively). The rs11091046 polymorphism is located in the 3′-untranslated region of AGTR2 exon 3, at a microRNA-response-element position possibly corresponding to the hsa-miR-208a-5p and hsa-miR-208b-5p binding sites [43]. The miR-208a and miR-208b elements are encoded in introns of the myosin heavy chain 6 gene (MYH6) or the myosin heavy chain 7 gene (MYH7), respectively [44,45]. Van Rooij et al. showed that miR-208a is required, i.a., for cardiomyocyte hypertrophy and fibrosis [44], while miR-208b is rather involved in the control of muscle myosin content [45]. Therefore, Yvert et al. suggested that AGTR2 expression may be influenced partly by miR-208 a- and/or b-5p and that the C allele of the AGTR2:rs11091046 polymorphism (in linkage disequilibrium with the 1675A allele) can reduce the binding affinity of miRNA to mRNA, leading to an increased amount of type-2 angiotensin II receptor protein [43]. It is also worthy to note that the AGTR2:rs11091046 polymorphism has been previously found to be associated with several cardiovascular phenotypes such as acute myocardial infarction [46], hypertension [47] or hypertrophic cardiomyopathy [48]. In the latter study, carried out with 103 genetically independent subjects with HCM, Deinum et al. showed a significant decrease in LVMI with the number of AGTR2:3123C alleles in women only but no association of this index with rs11091046 in men [48].
A major limitation of our study is its relatively low statistical power mainly due to a relatively small sample size (96 female newborns and 111 male newborns). Such limited numbers of subjects in our study were due to the fact that the recruitment of newborns to the study had been completed several years ago, and good-quality genomic DNA samples remained only in these 207 newborns for which we also had the results of ultrasound measurements of heart dimensions. To further depict the issue, we have computed (using the Open Epi tool, version 3.01, a free and open-source software available at www.openepi.com, accessed on 12 February 2025) the minimum sample size of male newborns for 80% statistical power and 5% type I error rate with the assumptions that the ratio of G to A hemizygotes is equal to 1.09 (58/53) and LVM/BL is lower than 15.5 g/m in 29.3% (17 of 58) of G subjects and in 37.7% (20 of 53) of A subjects (Table 5). Under the above assumptions, the minimum sample size necessary varied from 992 to 1039 male newborns (517–542 G subjects and 475–497 A subjects). On the other hand, the sample size in our study (n = 211) was even greater than in four of eight previously published reports focusing on association analyses of AGTR2:rs14003543 or AGTR2:rs11091046 with LVM or LVH [18,19,20,21,22,23,24,25]. It is also worth noting that the number of female newborns in our study (n = 96) was greater than in the study by Alfakih et al. (n = 72) or by Deinum et al. (n = 40), who previously revealed the association of lower LVM in women with the 1675A allele [20] or with the 3123C variant [48], respectively.
5. Conclusions
The results of our study suggest that the AGTR2:rs1403543 polymorphism may be associated with physiological variability in cardiac mass in female newborns. However, we are fully aware that the inclusion of AGTR2 polymorphism analysis into a cardiovascular risk assessment will require prior prospective longitudinal studies in much larger groups of newborns of specific ethnic origin, taking into account both the period and the degree of exposure to cardiovascular risk factors.
Author Contributions
Conceptualization, I.G., B.Ł. and A.C.; formal analysis, K.M.; investigation, B.Ł., K.L. and M.R.; methodology, I.G., B.Ł. and A.C.; supervision, I.G. and A.C. writing—original draft, I.G., K.M., K.L., M.R., B.Ł. and A.C.; writing—review and editing, K.M. and A.C. All authors have read and agreed to the published version of the manuscript.
Funding
This research received no external funding.
Institutional Review Board Statement
This study was approved by the bioethics committee at the Pomeranian Medical University, Szczecin, Poland (decision No. BN-001/57/05).
Informed Consent Statement
Informed consent was obtained from parents of all newborns involved in the study.
Data Availability Statement
The data are available from the corresponding author upon reasonable request.
Acknowledgments
One version of the manuscript has been checked by an English Academic Editor.
Conflicts of Interest
The authors declare no conflicts of interest.
Abbreviations
The following abbreviations are used in this manuscript:
| AGTR2 | Type-2 Angiotensin II Receptor gene |
| LVM | Left Ventricular Mass |
| PCR | Polymerase Chain Reaction |
| RFLP | Restriction Fragment Length Polymorphism |
| BM | Body Mass |
| BL | Body Length |
| BSA | Body Surface Area |
| LVH | Left Ventricular Hypertrophy |
| RAS | Renin–Angiotensin System |
| ANGII | Angiotensin II |
| AT1R | Type-1 Angiotensin II Receptor |
| AT2R | Type-2 Angiotensin II Receptor |
| LVMI | Left Ventricular Mass Index |
| GLAOLD | Glasgow Heart Scan Old |
| MRI | Magnetic Resonance Imaging |
| EPOGH | European Project On Genes in Hypertension |
| CVD | Cardiovascular Disease |
| IVST | Interventricular Septal Thickness |
| LVPWT | Left Ventricular Posterior Wall Thickness |
| LVID | Left Ventricular Internal Dimension |
| ICSBP | Interferon Consensus Sequence Binding Protein |
| ELP | Embryonal, Long Terminal Repeat Binding Protein |
| cDNA | Complementary deoxyribonucleic acid |
| mRNA | Messenger ribonucleic acid |
| D′ | The difference between the observed and the expected frequency of a given haplotype |
| r2 | The correlation between a pair of loci |
| LD | Linkage Disequilibrium |
| dbSNP | Single-Nucleotide Polymorphism database |
| TSI | Toscani in Italy |
| CEU | Utah Residents with Northern and Western European ancestry |
| GBR | British in England and Scotland |
| MYH6 | Myosin Heavy Chain 6 gene |
| MYH7 | Myosin Heavy Chain 7 gene |
| Hsa-miR | Homo sapiens microRNA (messenger ribonucleic acid) |
References
- Bula, K.; Ćmiel, A.; Sejud, M.; Sobczyk, K.; Ryszkiewicz, S.; Szydło, K.; Wita, M.; Mizia-Stec, K. Electrocardiographic criteria for left ventricular hypertrophy in aortic valve stenosis: Correlation with echocardiographic parameters. Ann. Noninvasive Electrocardiol. 2019, 24, e12645. [Google Scholar] [CrossRef] [PubMed]
- Lang, R.M.; Bierig, M.; Devereux, R.B.; Flachskampf, F.A.; Foster, E.; Pellikka, P.A.; Picard, M.H.; Roman, M.J.; Seward, J.; Shanewise, J.S.; et al. Recommendations for chamber quantification: A report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J. Am. Soc. Echocardiogr. 2005, 18, 1440–1463. [Google Scholar] [CrossRef]
- Bornstein, A.B.; Rao, S.S.; Marwaha, K. Left Ventricular Hypertrophy. In StatPearls [Internet]; StatPearls Publishing: Treasure Island, FL, USA, 2025. Available online: https://www.ncbi.nlm.nih.gov/books/NBK557534/ (accessed on 12 February 2025).
- Swan, L.; Birnie, D.H.; Padmanabhan, S.; Inglis, G.; Connell, J.M.; Hillis, W.S. The genetic determination of left ventricular mass in healthy adults. Eur. Heart J. 2003, 24, 577–582. [Google Scholar] [CrossRef] [PubMed]
- Sharma, P.; Middelberg, R.P.; Andrew, T.; Johnson, M.R.; Christley, H.; Brown, M.J. Heritability of left ventricular mass in a large cohort of twins. J. Hypertens. 2006, 24, 321–324. [Google Scholar] [CrossRef] [PubMed]
- Bella, J.N.; MacCluer, J.W.; Roman, M.J.; Almasy, L.; North, K.E.; Best, L.G.; Lee, E.T.; Fabsitz, R.R.; Howard, B.V.; Devereux, R.B. Heritability of left ventricular dimensions and mass in American Indians: The Strong Heart Study. J. Hypertens. 2004, 22, 281–286. [Google Scholar] [CrossRef]
- Assimes, T.L.; Narasimhan, B.; Seto, T.B.; Yoon, S.; Curb, J.D.; Olshen, R.A.; Quertermous, T. Heritability of left ventricular mass in Japanese families living in Hawaii: The SAPPHIRe Study. J. Hypertens. 2007, 25, 985–992. [Google Scholar] [CrossRef]
- Verhaaren, H.A.; Schieken, R.M.; Mosteller, M.; Hewitt, J.K.; Eaves, L.J.; Nance, W.E. Bivariate genetic analysis of left ventricular mass and weight in pubertal twins (the Medical College of Virginia twin study). Am. J. Cardiol. 1991, 68, 661–668. [Google Scholar] [CrossRef]
- Alexander, B.T.; South, A.M.; August, P.; Bertagnolli, M.; Ferranti, E.P.; Grobe, J.L.; Jones, E.J.; Loria, A.S.; Safdar, B.; Sequeira-Lopez, M.L.S.; et al. Appraising the Preclinical Evidence of the Role of the Renin-Angiotensin-Aldosterone System in Antenatal Programming of Maternal and Offspring Cardiovascular Health Across the Life Course: Moving the Field Forward: A Scientific Statement from the American Heart Association. Hypertension 2023, 80, e75–e89. [Google Scholar] [CrossRef]
- Bader, M.; Steckelings, U.M.; Alenina, N.; Santos, R.A.S.; Ferrario, C.M. Alternative Renin-Angiotensin System. Hypertension 2024, 81, 964–976. [Google Scholar] [CrossRef]
- Steckelings, U.M.; Widdop, R.E.; Sturrock, E.D.; Lubbe, L.; Hussain, T.; Kaschina, E.; Unger, T.; Hallberg, A.; Carey, R.M.; Sumners, C. The Angiotensin AT2 Receptor: From a Binding Site to a Novel Therapeutic Target. Pharmacol. Rev. 2022, 74, 1051–1135. [Google Scholar] [CrossRef]
- Biermann, D.; Heilmann, A.; Didié, M.; Schlossarek, S.; Wahab, A.; Grimm, M.; Römer, M.; Reichenspurner, H.; Sultan, K.R.; Steenpass, A.; et al. Impact of AT2 receptor deficiency on postnatal cardiovascular development. PLoS ONE 2012, 7, e47916. [Google Scholar] [CrossRef]
- Hein, L.; Barsh, G.S.; Pratt, R.E.; Dzau, V.J.; Kobilka, B.K. Behavioural and cardiovascular effects of disrupting the angiotensin II type-2 receptor in mice. Nature 1995, 377, 744–747. [Google Scholar] [CrossRef] [PubMed]
- Ichiki, T.; Labosky, P.A.; Shiota, C.; Okuyama, S.; Imagawa, Y.; Fogo, A.; Niimura, F.; Ichikawa, I.; Hogan, B.L.; Inagami, T. Effects on blood pressure and exploratory behaviour of mice lacking angiotensin II type-2 receptor. Nature 1995, 377, 748–750. [Google Scholar] [CrossRef]
- Akishita, M.; Yamada, H.; Dzau, V.J.; Horiuchi, M. Increased vasoconstrictor response of the mouse lacking angiotensin II type 2 receptor. Biochem. Biophys. Res. Commun. 1999, 261, 345–349. [Google Scholar] [CrossRef] [PubMed]
- Balmforth, A.J. Angiotensin II type 2 receptor gene polymorphisms in cardiovascular disease. J. Renin Angiotensin Aldosterone Syst. 2010, 11, 79–85. [Google Scholar] [CrossRef] [PubMed]
- Phan, L.; Zhang, H.; Wang, Q.; Villamarin, R.; Hefferon, T.; Ramanathan, A.; Kattman, B. The evolution of dbSNP: 25 years of impact in genomic research. Nucleic Acids Res. 2025, 53, D925–D931. [Google Scholar] [CrossRef]
- Schmieder, R.E.; Erdmann, J.; Delles, C.; Jacobi, J.; Fleck, E.; Hilgers, K.; Regitz-Zagrosek, V. Effect of the angiotensin II type 2-receptor gene (+1675 G/A) on left ventricular structure in humans. J. Am. Coll. Cardiol. 2001, 37, 175–182. [Google Scholar] [CrossRef]
- Herrmann, S.M.; Nicaud, V.; Schmidt-Petersen, K.; Pfeifer, J.; Erdmann, J.; McDonagh, T.; Dargie, H.J.; Paul, M.; Regitz-Zagrosek, V. Angiotensin II type 2 receptor gene polymorphism and cardiovascular phenotypes: The GLAECO and GLAOLD studies. Eur. J. Heart Fail. 2002, 4, 707–712. [Google Scholar] [CrossRef]
- Alfakih, K.; Maqbool, A.; Sivananthan, M.; Walters, K.; Bainbridge, G.; Ridgway, J.; Balmforth, A.J.; Hall, A.S. Left ventricle mass index and the common, functional, X-linked angiotensin II type-2 receptor gene polymorphism (-1332 G/A) in patients with systemic hypertension. Hypertension 2004, 43, 1189–1194. [Google Scholar] [CrossRef]
- Kuznetsova, T.; Staessen, J.A.; Thijs, L.; Kunath, C.; Olszanecka, A.; Ryabikov, A.; Tikhonoff, V.; Stolarz, K.; Bianchi, G.; Casiglia, E.; et al. Left ventricular mass in relation to genetic variation in angiotensin II receptors, renin system genes, and sodium excretion. Circulation 2004, 110, 2644–2650. [Google Scholar] [CrossRef]
- Ott, C.; Titze, S.I.; Schwarz, T.K.; Kreutz, R.; Hilgers, K.F.; Schmidt, B.M.; Schlaich, M.P.; Schmieder, R.E. High sodium intake modulates left ventricular mass in patients with G expression of +1675 G/A angiotensin II receptor type 2 gene. J. Hypertens. 2007, 25, 1627–1632. [Google Scholar] [CrossRef]
- Orlowska-Baranowska, E.; Placha, G.; Baranowski, R.; Michalek, P.; Gora, J.; Gaciong, Z.; Stepinska, J. Can angiotensin II +1675 G/A type 2 receptor gene polymorphism be a marker of left ventricular hypertrophy in patients with aortic stenosis? J. Heart Valve Dis. 2007, 16, 495–503. [Google Scholar] [PubMed]
- Carstens, N.; van der Merwe, L.; Revera, M.; Heradien, M.; Goosen, A.; Brink, P.A.; Moolman-Smook, J.C. Genetic variation in angiotensin II type 2 receptor gene influences extent of left ventricular hypertrophy in hypertrophic cardiomyopathy independent of blood pressure. J. Renin Angiotensin Aldosterone Syst. 2011, 12, 274–280. [Google Scholar] [CrossRef] [PubMed]
- Huber, M.; Völler, H.; Jakob, S.; Reibis, R.; Do, V.; Bolbrinker, J.; Zergibel, I.; Schmieder, R.E.; Treszl, A.; Wegscheider, K.; et al. Role of the angiotensin II type 2 receptor gene (+1675G/A) polymorphism on left ventricular hypertrophy and geometry in treated hypertensive patients. J. Hypertens. 2010, 28, 1221–1229. [Google Scholar] [CrossRef] [PubMed]
- Dwyer, T.; Sun, C.; Magnussen, C.G.; Raitakari, O.T.; Schork, N.J.; Venn, A.; Burns, T.L.; Juonala, M.; Steinberger, J.; Sinaiko, A.R.; et al. Cohort Profile: The international childhood cardiovascular cohort (i3C) consortium. Int. J. Epidemiol. 2013, 42, 86–96. [Google Scholar] [CrossRef]
- Lai, C.C.; Sun, D.; Cen, R.; Wang, J.; Li, S.; Fernandez-Alonso, C.; Chen, W.; Srinivasan, S.R.; Berenson, G.S. Impact of long-term burden of excessive adiposity and elevated blood pressure from childhood on adulthood left ventricular remodeling patterns: The Bogalusa Heart Study. J. Am. Coll. Cardiol. 2014, 64, 1580–1587. [Google Scholar] [CrossRef]
- Hanevold, C.; Waller, J.; Daniels, S.; Portman, R.; Sorof, J. The effects of obesity, gender, and ethnic group on left ventricular hypertrophy and geometry in hypertensive children: A collaborative study of the International Pediatric Hypertension Association. Pediatrics 2004, 113, 328–333. [Google Scholar] [CrossRef]
- Dhuper, S.; Abdullah, R.A.; Weichbrod, L.; Mahdi, E.; Cohen, H.W. Association of obesity and hypertension with left ventricular geometry and function in children and adolescents. Obesity 2011, 19, 128–133. [Google Scholar] [CrossRef]
- Li, X.; Li, S.; Ulusoy, E.; Chen, W.; Srinivasan, S.R.; Berenson, G.S. Childhood adiposity as a predictor of cardiac mass in adulthood: The Bogalusa Heart Study. Circulation 2004, 110, 3488–3492. [Google Scholar] [CrossRef]
- Toprak, A.; Wang, H.; Chen, W.; Paul, T.; Srinivasan, S.; Berenson, G. Relation of childhood risk factors to left ventricular hypertrophy (eccentric or concentric) in relatively young adulthood (from the Bogalusa Heart Study). Am. J. Cardiol. 2008, 101, 1621–1625. [Google Scholar] [CrossRef]
- Gorący, I.; Safranow, K.; Dawid, G.; Skonieczna-Żydecka, K.; Kaczmarczyk, M.; Gorący, J.; Loniewska, B.; Ciechanowicz, A. Common genetic variants of the BMP4, BMPR1A, BMPR1B, and ACVR1 genes, left ventricular mass, and other parameters of the heart in newborns. Genet. Test. Mol. Biomark. 2012, 16, 1309–1316. [Google Scholar] [CrossRef] [PubMed]
- Gorący, I.; Łoniewska, B.; Lewandowska, K.; Boroń, A.; Grzegorczyk, M.; Nowak, R.; Clark, J.S.C.; Ciechanowicz, A. Association of the rs3039851 Insertion/Deletion in the Gene PPP3R1, Which Encodes the Regulatory Calcineurin Subunit B Type 1, with Left Ventricular Mass in Polish Full-Term Newborns. Biomedicines 2023, 11, 1415. [Google Scholar] [CrossRef]
- Mosteller, R.D. Simplified calculation of body-surface area. N. Engl. J. Med. 1987, 317, 1098. [Google Scholar] [CrossRef] [PubMed]
- Hand, B.D.; Kostek, M.C.; Ferrell, R.E.; Delmonico, M.J.; Douglass, L.W.; Roth, S.M.; Hagberg, J.M.; Hurley, B.F. Influence of promoter region variants of insulin-like growth factor pathway genes on the strength-training response of muscle phenotypes in older adults. J. Appl. Physiol. 2007, 103, 1678–1687. [Google Scholar] [CrossRef]
- Huwez, F.U.; Houston, A.B.; Watson, J.; McLaughlin, S.; Macfarlane, P.W. Age and body surface area related normal upper and lower limits of M mode echocardiographic measurements and left ventricular volume and mass from infancy to early adulthood. Br. Heart J. 1994, 72, 276–280. [Google Scholar] [CrossRef]
- Han, T.; Wang, X.; Cui, Y.; Ye, H.; Tong, X.; Piao, M. Relationship between angiotensin-converting enzyme gene insertion or deletion polymorphism and insulin sensitivity in healthy newborns. Pediatrics 2007, 119, 1089–1094. [Google Scholar] [CrossRef] [PubMed]
- Wu, E.X.; Stanar, P.; Ma, S. X-chromosome inactivation in female newborns conceived by assisted reproductive technologies. Fertil. Steril. 2014, 101, 1718–1723. [Google Scholar] [CrossRef]
- Martin, M.M.; Elton, T.S. The sequence and genomic organization of the human type 2 angiotensin II receptor. Biochem. Biophys. Res. Commun. 1995, 209, 554–562. [Google Scholar] [CrossRef]
- Warnecke, C.; Willich, T.; Holzmeister, J.; Bottari, S.P.; Fleck, E.; Regitz-Zagrosek, V. Efficient transcription of the human angiotensin II type 2 receptor gene requires intronic sequence elements. Biochem. J. 1999, 340, 17–24. [Google Scholar] [CrossRef]
- Nishimura, H.; Yerkes, E.; Hohenfellner, K.; Miyazaki, Y.; Ma, J.; Hunley, T.E.; Yoshida, H.; Ichiki, T.; Threadgill, D.; Phillips, J.A., III; et al. Role of the angiotensin type 2 receptor gene in congenital anomalies of the kidney and urinary tract, CAKUT, of mice and men. Mol. Cell 1999, 3, 1–10. [Google Scholar] [CrossRef]
- Warnecke, C.; Mugrauer, P.; Sürder, D.; Erdmann, J.; Schubert, C.; Regitz-Zagrosek, V. Intronic ANG II type 2 receptor gene polymorphism 1675 G/A modulates receptor protein expression but not mRNA splicing. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2005, 289, R1729–R1735. [Google Scholar] [CrossRef] [PubMed]
- Yvert, T.P.; Zempo, H.; Gabdrakhmanova, L.J.; Kikuchi, N.; Miyamoto-Mikami, E.; Murakami, H.; Naito, H.; Cieszczyk, P.; Leznicka, K.; Kostryukova, E.S.; et al. AGTR2 and sprint/power performance: A case-control replication study for rs11091046 polymorphism in two ethnicities. Biol. Sport 2018, 35, 105–109. [Google Scholar] [CrossRef]
- van Rooij, E.; Sutherland, L.B.; Qi, X.; Richardson, J.A.; Hill, J.; Olson, E.N. Control of stress-dependent cardiac growth and gene expression by a microRNA. Science 2007, 316, 575–579. [Google Scholar] [CrossRef] [PubMed]
- van Rooij, E.; Quiat, D.; Johnson, B.A.; Sutherland, L.B.; Qi, X.; Richardson, J.A.; Kelm, R.J., Jr.; Olson, E.N. A family of microRNAs encoded by myosin genes governs myosin expression and muscle performance. Dev. Cell 2009, 17, 662–673. [Google Scholar] [CrossRef] [PubMed]
- Aoki, S.; Mukae, S.; Itoh, S.; Sato, R.; Nishio, K.; Ueda, H.; Iwata, T.; Katagiri, T. Genetic background in patients with acute myocardial infarction. Jpn. Heart J. 2001, 42, 15–28. [Google Scholar] [CrossRef] [PubMed]
- Jin, J.J.; Nakura, J.; Wu, Z.; Yamamoto, M.; Abe, M.; Chen, Y.; Tabara, Y.; Yamamoto, Y.; Igase, M.; Bo, X.; et al. Association of angiotensin II type 2 receptor gene variant with hypertension. Hypertens. Res. 2003, 26, 547–552. [Google Scholar] [CrossRef]
- Deinum, J.; van Gool, J.M.; Kofflard, M.J.; ten Cate, F.J.; Danser, A.H. Angiotensin II type 2 receptors and cardiac hypertrophy in women with hypertrophic cardiomyopathy. Hypertension 2001, 38, 1278–1281. [Google Scholar] [CrossRef]
Figure 1.
LVM/BM index in female newborns in regard to AGTR2:rs1403543 polymorphism. Box plots show medians (m), interquartile range (q0.25 to q0.75), range (whiskers) between q × 0.25 − 1.5 × (m – q × 0.25) to q × 0.75 + 1.5 × (q × 0.75 − m) and outliers.
Figure 1.
LVM/BM index in female newborns in regard to AGTR2:rs1403543 polymorphism. Box plots show medians (m), interquartile range (q0.25 to q0.75), range (whiskers) between q × 0.25 − 1.5 × (m – q × 0.25) to q × 0.75 + 1.5 × (q × 0.75 − m) and outliers.
Table 1.
Clinical and echocardiographic characteristics of the newborns with regard to sex.
| Variable | All Newborns (n = 207) | Female Newborns (n = 96) | Male Newborns (n = 111) | p |
|---|---|---|---|---|
| Median (Minimum–Maximum) | ||||
| BM [kg] | 3.43 (1.87–5.09) | 3.30 (1.87–4.48) | 3.51 (2.36–5.09) | 0.003 |
| BL [m] | 0.56 (0.44–0.63) | 0.55 (0.46–0.63) | 0.56 (0.44–0.63) | 0.055 |
| BSA [m2] | 0.230 (0.158–0.289) | 0.227 (0.158–0.270) | 0.232 (0.170–0.289) | 0.006 |
| IVST [mm] | 3.7 (2.4–6.3) | 3.6 (2.4–6.0) | 3.7 (2.6–6.3) | 0.592 |
| LVPWT [mm] | 2.8 (1.1–5.8) | 2.5 (1.3–5.0) | 2.8 (1.1–5.8) | 0.309 |
| LVID [mm] | 18.3 (15.0–25.0) | 18.1 (15.0–25.0) | 18.4 (15.6–23.5) | 0.168 |
| LVM [g] | 9.2 (4.5–21.9) | 8.8 (4.5–19.3) | 9.4 (4.5–21.9) | 0.062 |
| LVM/BM [g/kg] | 2.8 (1.5–6.4) | 2.7 (1.5–5.8) | 2.8 (1.6–6.4) | 0.804 |
| LVM/BL [g/m] | 16.5 (8.5–35.9) | 16.0 (9.0–33.3) | 17.1 (8.5–35.9) | 0.108 |
| LVM/BSA [g/m2] | 40.5 (22.2–90.6) | 39.4 (22.2–80.7) | 41.7 (22.4–90.6) | 0.384 |
Legend: BM = body mass; BL = body length; BSA = body surface area; IVST = interventricular septal thickness; LVPWT = left ventricular posterior wall thickness; LVID = left ventricular internal dimension; LVM = left ventricular mass. The p values are from Mann–Whitney tests. Parameter values given to 1 decimal place (d.p.), apart from BM/BL (2 d.p.) and BSA and p-values to 3 d.p.
Table 2.
Clinical and echocardiographic characteristics of the female newborns in regard to the AGTR2:rs1403543 (1675G>A) polymorphism.
Table 2.
Clinical and echocardiographic characteristics of the female newborns in regard to the AGTR2:rs1403543 (1675G>A) polymorphism.
| Variable | GG (n = 28) | GA (n = 45) | AA (n = 23) | p K-W | p D | p R |
|---|---|---|---|---|---|---|
| Median (Minimum–Maximum) | ||||||
| BM [kg] | 3.26 (1.87–4.30) | 3.30 (2.30–4.22) | 3.50 (2.70–4.48) | 0.338 | 0.377 | 0.158 |
| BL [m] | 0.55 (0.46–0.63) | 0.55 (0.47–0.62) | 0.55 (0.50–0.60) | 0.761 | 0.276 | 0.463 |
| BSA [m2] | 0.225 (0.158–0.270) | 0.225 (0.173–0.270) | 0.230 (0.194–0.268) | 0.393 | 0.491 | 0.179 |
| IVST [mm] | 3.8 (2.8–6.0) | 3.4 (2.4–4.8) | 3.7 (2.4–6.0) | 0.085 | 0.069 | 0.603 |
| LVPWT [mm] | 2.8 (1.7–5.0) | 2.5 (1.3–3.8) | 2.5 (1.5–5.0) | 0.202 | 0.075 | 0.602 |
| LVID [mm] | 18.0 (15.0–21.4) | 18.5 (15.0–21.2) | 17.6 (16.0–25.0) | 0.298 | 0.939 | 0.156 |
| LVM [g] | 8.9 (5.6–17.6) | 8.8 (4.5–15.3) | 8.2 (5.4–19.3) | 0.331 | 0.138 | 0.619 |
| LVM/BM [g/kg] | 2.9 (1.8–5.8) | 2.7 (1.5–4.2) | 2.4 (1.7–5.2) | 0.112 | 0.043 | 0.233 |
| LVM/BL [g/m] | 16.6 (11.0–32.0) | 16.1 (9.0–26.4) | 15.1 (10.0–33.3) | 0.229 | 0.087 | 0.577 |
| LVM/BSA [g/m2] | 40.8 (26.6–80.7) | 39.8 (22.2–63.1) | 35.7 (26.2–78.8) | 0.193 | 0.076 | 0.361 |
Legend: For abbreviations and numbers of decimal places see Table 1. The p K-W values are from Kruskal–Wallis tests, and the p D or p R values are from Mann–Whitney tests in dominant or recessive mode of inheritance for the AGTR2:1675A allele (AA + GA versus GG, or AA versus GG + GA, respectively).
Table 3.
Clinical and echocardiographic characteristics of the male newborns in regard to the AGTR2:rs1403543 (1675G>A) polymorphism.
Table 3.
Clinical and echocardiographic characteristics of the male newborns in regard to the AGTR2:rs1403543 (1675G>A) polymorphism.
| Variable | G (n = 58) | A (n = 53) | p |
|---|---|---|---|
| Median (Minimum–Maximum) | |||
| BM [kg] | 3.64 (2.36–5.09) | 3.45 (2.73–4.40) | 0.073 |
| BL [m] | 0.57 (0.44–0.63) | 0.56 (0.47–0.61) | 0.071 |
| BSA [m2] | 0.242 (0.170–0.289) | 0.229 (0.196–0.269) | 0.047 |
| IVST [mm] | 3.8 (2.0–6.3) | 3.7 (2.7–5.6) | 0.947 |
| LVPWT [mm] | 2.8 (2.0–4.3) | 2.8 (1.1–5.8) | 0.270 |
| LVID [mm] | 18.6 (15.6–23.5) | 18.0 (15.6–23.2) | 0.307 |
| LVM [g] | 9.8 (5.0–21.9) | 9.4 (4.5–19.0) | 0.392 |
| LVM/BM [g/kg] | 2.8 (1.8–6.4) | 2.7 (1.6–4.7) | 0.947 |
| LVM/BL [g/m] | 17.4 (9.2–36.9) | 16.9 (8.5–33.4) | 0.567 |
| LVM/BSA [g/m2] | 41.8 (25.0–90.6) | 41.2 (22.4–72.8) | 0.849 |
Legend: For abbreviations and number of decimal places, see Table 1.
Table 4.
Frequency distributions of AGTR2:rs1403543 genotypes in female newborns in regard to tertiles of left ventricular mass (LVM) indices.
Table 4.
Frequency distributions of AGTR2:rs1403543 genotypes in female newborns in regard to tertiles of left ventricular mass (LVM) indices.
| Variable | Tertile | GG n (%) | GA n (%) | AA n (%) | p | p D | p R |
|---|---|---|---|---|---|---|---|
| LT vs. MT vs. UT (LT vs. UT) | LT vs. MT vs. UT (LT vs. UT) | LT vs. MT vs. UT (LT vs. UT) | |||||
| Lower (<2.4) | 6 (19) | 15 (47) | 11 (34) | 0.179 (0.150) | 0.155 (0.055) | 0.202 (0.266) | |
| LVM/BM [g/kg] | Middle (2.4–3.0) | 9 (28) | 18 (56) | 5 (16) | |||
| Upper (>3.0) | 13 (41) | 12 (38) | 7 (22) | ||||
| Lower (<14.7) | 5 (16) | 17 (53) | 10 (31) | 0.226 (0.138) | 0.114 (0.047) | 0.337 (0.578) | |
| LVM/BL [g/m] | Middle (14.7–18.4) | 11 (34) | 16 (60) | 5 (16) | |||
| Upper (>18.4) | 12 (38) | 12 (38) | 8 (25) | ||||
| Lower (<35.6) | 5 (16) | 17 (53) | 10 (31) | 0.315 (0.139) | 0.114 (0.047) | 0.475 (0.396) | |
| LVM/BSA [g/m2] | Middle (35.6–44.6) | 11 (34) | 15 (47) | 6 (19) | |||
| Upper (>44.6) | 12 (38) | 13 (41) | 7 (22) |
Legend: For abbreviations see Table 1. The p, p D or p R values are from chi-squared tests for comparisons of GG versus GA versus AA and for comparisons in dominant or recessive mode of inheritance for the AGTR2:1675A allele (AA + GA versus GG, or AA versus GA + GG, respectively). LT versus MT versus UT or LT versus UT are for comparisons of lower tertile versus middle tertile versus upper tertile or for comparisons of lower tertile versus upper tertile, respectively. Parameter values given to 0 decimal places.
Table 5.
Frequency distributions of AGTR2:rs1403543 variants in hemizygous male newborns in regard to tertiles of left ventricular mass indices.
Table 5.
Frequency distributions of AGTR2:rs1403543 variants in hemizygous male newborns in regard to tertiles of left ventricular mass indices.
| Variable | Tertile | G n (%) | A n (%) | p LT vs. MT vs. UT | p LT vs. UT |
|---|---|---|---|---|---|
| Lower (<2.5) | 22 (60) | 15 (40) | |||
| LVM/BM [g/kg] | Middle (2.5–3.0) | 15 (40) | 22 (60) | 0.212 | 0.814 |
| Upper (>3.0) | 21 (57) | 16 (43) | |||
| Lower (<15.5) | 17 (46) | 20 (54) | |||
| LVM/BL [g/m] | Middle (15.5–18.9) | 19 (51) | 18 (49) | 0.504 | 0.244 |
| Upper (>18.9) | 22 (60) | 15 (40) | |||
| Lower (<37.4) | 20 (54) | 17 (46) | |||
| LVM/BSA [g/m2] | Middle (37.4–45.4) | 16 (43) | 21 (57) | 0.364 | 0.639 |
| Upper (>45.4) | 22 (60) | 15 (40) |
Legend: For abbreviations, see Table 1. The p values are from chi-squared tests for comparisons of lower tertile versus middle tertile versus upper tertile or lower tertile versus upper tertile (LT versus MT versus UT or LT versus UT, respectively). Parameter values given to 0 decimal places; p-values to 3 decimal places.
Table 6.
Clinical and echocardiographic characteristics of the newborns with regard to sex after exclusion of AGTR2 GA heterozygous females.
Table 6.
Clinical and echocardiographic characteristics of the newborns with regard to sex after exclusion of AGTR2 GA heterozygous females.
| Variable | Female Newborns (n = 28 + 23) | Male Newborns (n = 111) | p |
|---|---|---|---|
| Median (Minimum–Maximum) | |||
| BM [kg] | 3.32 (1.87–4.48) | 3.51 (2.36–5.09) | 0.028 |
| BL [m] | 0.55 (0.46–0.63) | 0.56 (0.44–0.63) | 0.195 |
| BSA [m2] | 0.230 (0.158–0.270) | 0.230 (0.170–0.290) | 0.049 |
| IVST [mm] | 3.7 (2.4–6.0) | 3.7 (2.6–6.3) | 0.430 |
| LVPWT [mm] | 2.5 (1.5–5) | 2.8 (1.1–5.8) | 0.894 |
| LVID [mm] | 17.8 (15.0–25.0) | 18.4 (25.6–23.5) | 0.065 |
| LVM [g] | 8.7 (5.4–19.3) | 9.5 (4.5–21.9) | 0.360 |
| LVM/BM [g/kg] | 2.7 (1.7–5.8) | 2.8 (1.6–6.4) | 0.762 |
| LVM/BL [g/m] | 15.9 (10.0–33.3) | 17.1 (8.5–35.9) | 0.489 |
| LVM/BSA [g/m2] | 38.9 (26.2–80.8) | 41.7 (22.4–90.6) | 0.857 |
Legend: For abbreviations and number of decimal places, see Table 1.
Table 7.
Clinical and echocardiographic characteristics of the newborns in regard to AGTR2:rs1403543 (1675G>A) after exclusion of GA heterozygous females.
Table 7.
Clinical and echocardiographic characteristics of the newborns in regard to AGTR2:rs1403543 (1675G>A) after exclusion of GA heterozygous females.
| Variable | GG + G (n = 28 + 58) | AA + A (n = 23 + 53) | p |
|---|---|---|---|
| Median (Minimum–Maximum) | |||
| BM [kg] | 3.46 (1.87–5.09) | 3.47 (2.70–4.48) | 0.563 |
| BL [m] | 0.56 (0.44–0.63) | 0.56 (0.47–0.61) | 0.282 |
| BSA [m2] | 0.230 (0.158–0.290) | 0.230 (0.194–0.270) | 0.357 |
| IVST [mm] | 3.8 (2.6–6.3) | 3.7 (2.4–6.0) | 0.704 |
| LVPWT [mm] | 2.8 (1.7–5.0) | 2.7 (1.1–5.8) | 0.102 |
| LVID [mm] | 18.4 (15–23.5) | 18.0 (15.6–25.0) | 0.206 |
| LVM [g] | 9.5 (5.0–21.9) | 9.2 (4.5–19.3) | 0.207 |
| LVM/BM [g/kg] | 2.8 (1.8–6.4) | 2.7 (1.6–5.2) | 0.357 |
| LVM/BL [g/m] | 17.2 (9.2–35.9) | 16.2 (8.5–33.4) | 0.278 |
| LVM/BSA [g/m2] | 41.7 (25.0–90.6) | 40.1 (22.4–78.8) | 0.310 |
Legend: For abbreviations and number of decimal places, see Table 1.
Table 8.
Frequency distributions of AGTR2:rs1403543 variants in GG homozygous females and G hemizygous males and in AA homozygous females and A hemizygous males in regard to tertiles of total kidney volumes.
Table 8.
Frequency distributions of AGTR2:rs1403543 variants in GG homozygous females and G hemizygous males and in AA homozygous females and A hemizygous males in regard to tertiles of total kidney volumes.
| Variable | Tertile | GG + G n (%) | AA + A n (%) | p LT vs. MT vs. UT | p LT vs. UT |
|---|---|---|---|---|---|
| Lower (<2.4) | 27 (50) | 27 (50) | |||
| LVM/BM [g/kg] | Middle (2.4–3.0) | 27 (50) | 27 (50) | 0.538 | 0.334 |
| Upper (>3.0) | 32 (59) | 22 (41) | |||
| Lower (<15.4) | 25 (46) | 29 (54) | |||
| LVM/BL [g/m] | Middle (15.4–19.0) | 29 (54) | 25 (46) | 0.400 | 0.177 |
| Upper (>19.0) | 32 (59) | 22 (41) | |||
| Lower (<37.0) | 25 (46) | 29 (54) | |||
| LVM/BSA [g/m2] | Middle (37.0–45.5) | 28 (52) | 26 (48) | 0.297 | 0.123 |
| Upper (>45.5) | 33 (61) | 21 (39) |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
MDPI and ACS Style
Gorący, I.; Miler, K.; Lewandowska, K.; Rychel, M.; Łoniewska, B.; Ciechanowicz, A. The rs1403543 Polymorphism of AGTR2, Which Encodes the Type-2 Angiotensin II Receptor, and Left Ventricular Mass in Polish Full-Term Newborns. Genes 2025, 16, 518. https://doi.org/10.3390/genes16050518
AMA Style
Gorący I, Miler K, Lewandowska K, Rychel M, Łoniewska B, Ciechanowicz A. The rs1403543 Polymorphism of AGTR2, Which Encodes the Type-2 Angiotensin II Receptor, and Left Ventricular Mass in Polish Full-Term Newborns. Genes. 2025; 16(5):518. https://doi.org/10.3390/genes16050518
Chicago/Turabian StyleGorący, Iwona, Karol Miler, Klaudyna Lewandowska, Monika Rychel, Beata Łoniewska, and Andrzej Ciechanowicz. 2025. "The rs1403543 Polymorphism of AGTR2, Which Encodes the Type-2 Angiotensin II Receptor, and Left Ventricular Mass in Polish Full-Term Newborns" Genes 16, no. 5: 518. https://doi.org/10.3390/genes16050518
APA StyleGorący, I., Miler, K., Lewandowska, K., Rychel, M., Łoniewska, B., & Ciechanowicz, A. (2025). The rs1403543 Polymorphism of AGTR2, Which Encodes the Type-2 Angiotensin II Receptor, and Left Ventricular Mass in Polish Full-Term Newborns. Genes, 16(5), 518. https://doi.org/10.3390/genes16050518
Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.
